For the past two decades, immunotherapy has been the only therapeutic approach to demonstrate a moderate, but unequivocal benefit in a restricted patient population with clear-cell renal cell carcinoma ([@bib29]; [@bib14]). Indeed, after the cloning of the genes encoding interleukin (IL)-2 and interferon-alpha (IFN-*α*), extensive clinical investigations undertaken in metastatic renal cell carcinoma (mRCC) showed that these biological agents yielded response rates ranging from 8 to 26% with only modest effects on the natural history of the disease in terms of overall survival (OS) ([@bib13]). In a phase II non-randomised trial, [@bib8] reported long-term complete remissions with high doses of IL-2 administered intravenously, thus suggesting that the efficacy of IL-2 might correlate with doses and administration methods.

The multikinase inhibitor (TKI) sorafenib (Nexavar; Bayer HealthCare, Milan, Italy), which targets the Raf/MEK/ERK pathway as well as vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-b, c-Kit, Fit-3 and RET, has shown dual anti-proliferative and anti-angiogenic activity ([@bib28]). A pivotal, randomised, placebo-controlled, phase III clinical trial (the TARGET study) ([@bib4]) demonstrated a significant improvement in progression-free survival (PFS) with sorafenib (5.5 months) *vs* placebo (2.8 months; *P*\<0.001) in patients with clear-cell mRCC refractory or intolerant to cytokines. Following this trial, the drug was the first targeted therapy to be approved by the US Food and Drug Administration for the treatment of this disease. A subsequent randomised phase two trial comparing sorafenib with IFN-*α* as first-line treatment in mRCC demonstrated no differences in terms of PFS in the two arms of therapy (5.7 *vs* 5.6 months, *P*=0.50) ([@bib6]).

Preclinical investigations have provided evidence to support the combination of sorafenib with IL-2 ([@bib11]; [@bib2]). IL-2 acts to induce the proliferation and activation of T cells, B cells, natural killer (NK)-cells and lymphokine-activated killer cells, resulting in multiple biological effects including the proliferation of antigen-stimulated T cells and the induction of cytotoxicity through the activation of tumouricidal monocytes. This led to the hypothesis that the different mechanisms of action of sorafenib and IL-2 on T-cell signalling and proliferation could be synergistic, and provide improved clinical outcomes in patients with mRCC.

On the basis of these assumptions, this randomised, prospective, phase II, clinical study compared the combination of sorafenib plus IL-2 *vs* sorafenib alone in patients with mRCC not previously treated with systemic therapy.

Patients and methods
====================

Patients
--------

Eligible patients were aged 18 years or older, with a life expectancy of at least 3 months, and an Eastern Cooperative Oncology Group (ECOG) performance status of two or less. They were required to have a histologically confirmed diagnosis of advanced or metastatic RCC, all histologies, with at least one measurable unidimensional lesion detected by computed tomography (CT) or magnetic resonance imaging (MRI) scan and evaluated according to Response Evaluation Criteria for Solid Tumours (RECIST) criteria version 1.0 ([@bib27]). In cases of initial diagnosis of RCC dating back more than 2 years, cytohistological confirmation of RCC origin of the current lesions was mandatory. Eligible patients had not been previously treated with systemic therapy for metastatic disease, but patients could have undergone previous nephrectomy. The following baseline haematochemical values were considered mandatory for eligibility: absolute neutrophil count ⩾1.5 × 10^9^ l^−1^; platelet count ⩾100 × 10^9^ l^−1^; haemoglobin \>9 g dl^−1^; serum creatinine ⩽2.0 × the upper limit of normal (ULN); total bilirubin \<1.5 × ULN; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \<2.5 × ULN for patients without liver metastases and \<5 × ULN for patients with liver metastases; amylase and lipase \<1.5 × ULN. Exclusion criteria included a history of brain metastases, presence of concomitant illnesses, or medical conditions, such as serious respiratory or cardiovascular diseases, unstable angina, uncontrolled hypertension (⩾160 mm Hg systolic and/or 90 mm Hg diastolic pressure), unstable diabetes mellitus, serious bacterial or fungal infections, or potentially life-threatening autoimmune disorders. Patients with other previous malignancies were considered ineligible, with the exception of those with a history of adequately treated basal- or squamous-cell skin cancer or *in situ* cervical cancer.

Study design
------------

This was a prospective, randomised, open-label, multicentre, phase II study designed to evaluate the efficacy and safety of the combination of sorafenib plus IL-2 *vs* sorafenib alone in previously untreated patients with unresectable or metastatic RCC. The primary endpoint of the study was PFS, and the secondary endpoints included objective response rate (ORR), OS, and the safety profile of the two therapeutic regimens.

Patients were randomly allocated (1 : 1) to treatment with either oral sorafenib 400 mg (2 × 200 mg tablets) twice daily for the entire study period combined with IL-2 administered subcutaneously at a dose of 4.5 million international units (MIU) on 5 days per week for 6 weeks with treatment repeated every 8 weeks, or with sorafenib alone at the same dose as above. However, after treatment of the first 40 patients, of whom 20 were randomised to the combination treatment arm, the protocol was amended to reduce the dose of IL-2--3 MIU 5 days per week, 2 weeks on and 2 weeks off, because of the onset of AEs. Patients received study treatment until tumour progression, symptomatic deterioration, or onset of unacceptable toxicity requiring drug discontinuation and withdrawal of the patient from the study.

The study design was approved by the Ethical Committees of each Institution and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. At enrolment, each patient gave written informed consent. Randomisation was performed centrally at the Italian Trials in Medical Oncology (ITMO) office. To ensure balance between the treatment arms with respect to centre, Memorial Sloan-Kettering Cancer Centre (MSKCC) risk group (low--intermediate--high) and histological type (clear cell *vs* non-clear cell), the minimisation method was applied using the Minim program ([@bib7], freely available at: <http://www-users.york.ac.uk/~mb55/guide/minim.htm>, last access: 14 September 2010). The program was set by the Unit of Medical Statistics, Biometry and Bioinformatics. ITMO staffs were involved in running the program and assigning eligible patients to treatment arm.

Safety and efficacy assessments
-------------------------------

Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) (version 3.0). In the case of severe toxicities (grades 3--4) that were deemed likely to be related to sorafenib treatment, such as haematological toxicity, hypertension, and skin reactions, sorafenib was reduced to a dose of 400 mg once daily or every other day, or was temporarily discontinued. If a further dose reduction was required, or if no recovery (grades 0--1) was evident after a 2-week discontinuation of sorafenib, treatment was discontinued. No dose reduction of IL-2 was initially defined in the protocol; in the case of AEs related to IL-2: drug administration was temporarily stopped and then restarted at the same dosage after AE resolution. After the protocol amendment, the occurrence of grade 3--4 AEs resulted in dose reduction of IL-2 to 2 MIU on 5 days per week, 2 weeks on and 2 weeks off. If after 2 weeks no recovery (grades 0--1) was observed, the patient was withdrawn from the study.

RECIST criteria version 1.0 was used for response assessments. Evaluations were carried out every 8 weeks during the first 24 weeks of treatment and then every 12 weeks thereafter. Tumour measurements were carried out by CT or MRI scan, with all initial diagnoses of complete and partial responses confirmed 4 weeks later.

Statistical analysis
--------------------

Sample size was calculated according to a phase 2.5 design ([@bib25]) considering PFS as endpoint (progression or death without progression, whichever occurred first). Assuming exponentially distributed time and 10% significance level (one-sided log-rank test) to detect a 3-month increase in median PFS time in the experimental arm from an anticipated median of 6 months in the control arm ([@bib6]), 110 events yielded 80% power to detect the target difference, with a sample size of 128 patients recruited over 24 months, and with a maximum length of follow-up of 36 months.

The efficacy and safety analyses were performed on data from the intent-to-treat population. All clinical and instrumental variables and toxicity data were analysed by descriptive statistics: mean, s.d., minimum, and maximum values for continuous variables, and absolute and relative frequencies for categorical variables. Curves relevant to PFS were estimated by the Kaplan--Meier method and compared by means of the log-rank test. Reports of AEs were categorised according to type, severity, and outcome.

Results
=======

Patients
--------

From October 2006 to February 2008, 128 patients entered the study (66 receiving combination treatment with sorafenib plus IL-2, and 62 receiving sorafenib monotherapy), all of whom were included in the analyses. Four patients in both arms of treatment were unevaluable for response because of refusal or being lost to follow-up ([Figure 1](#fig1){ref-type="fig"}). Baseline characteristics of the two groups were well balanced with regards to age, sex, histology, previous surgery, tumour stage, site of metastatic disease, and risk category ([Table 1](#tbl1){ref-type="table"}). Overall 73 and 74% of all patients in the combination and single agent arms, respectively, were nephrectomised before study entry. In total, 20 (30%) and 9 (15%) patients had only lung disease in the combination and single agent arms, respectively, whereas 31 (47%) and 32 (52%) patients had multiple sites of disease in the combination and single agent arms, respectively.

Median duration of sorafenib alone or combination treatment was 29 and 35 weeks, respectively.

Medical treatment was withdrawn in 15 and 12% of patients in the combination and single agent arms, respectively, as a result of treatment refusal, AEs, or being lost to follow-up. A dose reduction was undertaken in 35 and 31% of patients in the combination and monotherapy arms, respectively.

A dose reduction in the first cohort of patients receiving sorafenib and higher dose of IL-2 was undertaken in 48% of the population because of toxicity.

Efficacy
--------

Median PFS was not significantly different between the two treatment groups (*P*=0.109): median PFS time was 33 weeks with the combination of sorafenib plus IL-2, compared with 30 weeks with sorafenib monotherapy. In all, 1- and 2-year PFS was 31.1% (95% CI: 21.5--45.1) and 22.5% (95% CI: 14.1--35.9), respectively, with combination therapy and 30.0% (95% CI: 20.2--44.6) and 11.3% (95% CI: 5.3--23.7) with sorafenib monotherapy ([Figure 2](#fig2){ref-type="fig"}).

With combination therapy, 18 patients (27.3%) had a partial response and 35 (53.0%) had stable disease. Six patients (9.1%) had a long-term partial response during at least 12 months. With sorafenib monotherapy, 9 patients (14.5%) achieved partial response and 37 (59.7%) had stable disease. The numbers of patients with disease progression were 9 (13.6%) and 12 (19.4%) in the combination and single arms, respectively. Tumour shrinkage is illustrated in [Figure 3](#fig3){ref-type="fig"}. After a median follow-up time of 27 months, median OS was not reached in either treatment group.

The subgroup analysis demonstrated that improvement in PFS was more evident in the population with low-risk disease than in those with intermediate- or high-risk disease, with a median PFS of 47 weeks in the combination therapy group compared with 41 weeks in the sorafenib monotherapy group ([Figure 4](#fig4){ref-type="fig"}). In contrast, in the population with intermediate-risk disease, median PFS was 21 weeks in the combination therapy group compared with 29 weeks in the sorafenib monotherapy group. PFS was not calculated in the high-risk subgroup because of the low number of patients in this category. Median PFS for patients with clear-cell histotype was 36 weeks with combination therapy and 32 weeks with sorafenib monotherapy. The small number of patients with non-clear-cell histotypes did not allow efficacy evaluations in these less frequent histologies. Considering the two subgroups of patients receiving the higher (full) or lower (reduced) doses of IL-2, median PFS was 43 weeks in the higher-dose subgroup and 31 weeks in the lower-dose subgroup ([Figure 5](#fig5){ref-type="fig"}).

Considering those patients who had only lung metastases, partial responses were observed in 5 out of 20 (25%) patients in the combination therapy arm and 1 out of 9 (11%) patients in the sorafenib arm. In this limited subgroup, tumour shrinkage was overall documented in 10 out of 20 (50%) patients receiving combination treatment.

Safety
------

The incidence of AEs in the sorafenib plus IL-2 combination therapy group was 80% for any grade and 38% for grade ⩾3 AEs. In the sorafenib monotherapy group, 92% of patients reported AEs of any grade and 25% reported grade ⩾3 AEs. The most common (incidence \>5%) grade ⩾3 AEs (combination *vs* monotherapy) were: skin (14 *vs* 9%), gastrointestinal (8 *vs* 5%), and general disorders (8 *vs* 3%). The overall AEs are shown in [Table 2](#tbl2){ref-type="table"}. For the first 20 patients treated with higher-dose IL-2, the most common AE requiring the protocol amendment was grade \>2 asthenia, which was reported in 11 patients (55%). After the amendment, the incidence and manageability of these AEs improved. Dose reduction due to AEs was undertaken in 22 patients (33%) in the combination therapy group and in 15 patients (24%) in the sorafenib monotherapy group.

Discussion
==========

Until recently, the prognosis of patients with mRCC was extremely poor because of the high resistance of this disease to the available therapeutic approaches, such as conventional cytotoxic chemotherapy, radiotherapy, and hormone therapy. The subsequent introduction of cytokines, particularly IL-2, produced varying efficacy and safety outcomes, raising a series of questions about the most appropriate doses and methods of administration. During recent years, advances in the understanding of the molecular biology of RCC have led to the successful development of several new anti-angiogenic factors with promising efficacy and acceptable toxicity profiles ([@bib10]; [@bib5]; [@bib19], [@bib17]; [@bib22]; [@bib26]). This has resulted in a shift from the use of cytokine-based therapies to these newer therapeutic approaches.

The current study is, to our knowledge, the first to evaluate the combination of sorafenib and IL-2 in mRCC. When the study was planned in 2006, there was limited knowledge regarding the possible synergistic action of sorafenib plus IL-2. This trial was not based on a previous phase I study or from any extrapolation from preclinical data. Therefore, the timing and dose of drug administration, and IL-2 dose modifications were established on rather empirical assumptions, chiefly based on concerns for safety of the combination and without any specific guidance. Given that, tolerability is difficult to interpret because of the heterogeneity of IL-2 doses and schedules used.

The results of the present study failed to meet the pre-specified statistical endpoints. The trend towards a superiority of the combination treatment in terms of median PFS did not reach statistical significance. The median PFS of 33 weeks observed in patients treated with the combination compared with 30 weeks for those treated with sorafenib alone (*P*=0.109), does not appear to support a synergistic effect of sorafenib and IL-2 in the overall study population. The subgroup analysis demonstrated that the difference in PFS was more evident in the population with low-risk disease than in those with intermediate-risk disease, with a median PFS of 47 weeks *vs* 41 weeks in favour of combination therapy. These findings suggest that in some subgroups of patients with slowly progressing disease, there may be a benefit to using cytokines. In contrast, the population with intermediate-risk disease had a median PFS of 21 *vs* 29 weeks in favour of sorafenib monotherapy.

This analysis suggest a detrimental effect of the addition of IL-2 in the population with intermediate prognostic features, consistent with a previous study that showed that IL-2 treatment had no benefit in patients with intermediate-risk disease ([@bib21]).

After treating the first 40 patients, a reduction in IL-2 dose to 3 MIU on 5 days per week, 2 weeks on followed by 2 weeks off, was necessary because of the onset of high rates of asthenia (55% of grade 3 or 4). The resulting median PFS was 43 weeks in patients receiving the higher dose of IL-2 plus sorafenib *vs* 31 weeks in patients who received the lower dose of IL-2 plus sorafenib, suggesting that the efficacy of the combination treatment could be associated with IL-2 dose. Therefore, assuming that a synergistic effect could be recognised, factors such as route of administration, schedule, and doses of IL-2 used could be called into question as responsible for the different results. Previous investigations of IL-2 have shown that by changing the schedule of the drug by either continuous infusion or subcutaneous administration it is possible to decrease toxicity while maintaining therapeutic efficacy. Moreover, comparisons between higher and lower doses of IL-2 have shown a higher response rate with higher doses without, however, any significant survival advantage ([@bib20]). In contrast, in selected patients, the use of high doses of IL-2 has provided long-term complete remission ([@bib23]).

By contrast, results from the AVOREN study demonstrated that a dose reduction of IFN-*α* did not influence the activity of the combination of bevacizumab plus IFN-*α* when administered as first-line treatment in mRCC ([@bib15]). Previous experience suggests that the activity of IL-2 could be also related to the site of disease ([@bib1]). Proof that lung metastases had more benefit from low-dose IL-2 in comparison with others sites of disease ([@bib16]). In our trial, 5 out of 20 (25%) patients who had only lung disease developed a partial response with the combination therapy, while 1 out of 9 (12%) patients in the sorafenib arm had a partial response. The limited number of patients with these characteristics means that we cannot draw any firm conclusions concerning the usefulness of the combination of sorafenib and IL-2 in patients with only lung disease. Similar to other trials combining sorafenib±IFN-*α*, the current results support the hypothesis that immunotherapy does not add much to sorafenib as first-line therapy ([@bib9]; [@bib24]; [@bib3]; [@bib12]). In addition, the combination of sunitinib and IFN-*α* was studied in a phase I trial and showed no evidence of a therapeutic synergistic effect and displayed a poor safety profile ([@bib18]).

In conclusion, in the present study, the combination of sorafenib plus IL-2 did not improve the clinical efficacy of sorafenib monotherapy as first-line treatment of mRCC. Subgroup analysis suggested that patients with clear-cell histology and those with good prognosis receiving higher doses of IL-2 may respond best to the combination therapy.
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###### Patient characteristics at baseline (intent-to-treat population)

                                      **Sorafenib+IL-2 (*n*=66)**   **Sorafenib (*n*=62)**
  ----------------------------------- ----------------------------- ------------------------
  *Age at randomisation (years)*                                    
   Median (interquartile range)       64 (57--69)                   62 (52--69)
                                                                     
  *Gender,* n (%)                                                   
   Male                               52 (79)                       43 (69)
   Female                             14 (21)                       19 (31)
                                                                     
  *Tumor stage at diagnosis,* n (%)                                 
   I                                  5 (8)                         3 (5)
   II                                 17 (26)                       10 (16)
   III                                14 (21)                       24 (39)
   IV                                 28 (42)                       25 (40)
   Missing                            2 (3)                         0
                                                                     
  *MSKCC risk group,* n (%)                                         
   Low                                36 (55)                       34 (55)
   Intermediate                       27 (41)                       24 (39)
   High                               3 (5)                         4 (6)
                                                                     
  *Histological type,* n (%)                                        
   Clear cell                         58 (88)                       56 (90)
   Non-clear cell                     8 (12)                        6 (10)
                                                                     
  *Previous nephrectomy,* n (%)                                     
   No                                 18 (27)                       16 (26)
  Yes                                 48 (73)                       46 (74)
                                                                     
  *Sites of disease,* n (%)                                         
   Lung                               20 (30)                       9 (15)
   Liver                              1 (2)                         3 (5)
   Lymph nodes                        7 (11)                        10 (16)
   Kidney                             1 (2)                         1 (2)
   Bone                               2 (3)                         3 (5)
   Other site                         4 (6)                         4 (6)
   Multiple sites                     31 (47)                       32 (52)

Abbreviations: IL-2=interleukin 2; MSKCC=Memorial Sloan Kettering Cancer Centre.

###### Adverse events (⩾5% in either treatment group)

                                        **Sorafenib+IL-2 (*n*=66)**   **Sorafenib (*n*=62)**             
  ------------------------------------- ----------------------------- ------------------------ --------- --------
  Fatigue, *n* (%)                      12 (19)                       2 (3)                    10 (16)   1 (2)
  Chest Pain, *n* (%)                   3 (5%)                        1 (2)                    0         0
  Influenza-like illness, *n* (%)       8 (12)                        \(2\)                    0         0
  Pyrexia, *n* (%)                      13 (20)                       0                        1 (2)     0
  Anemia, *n* (%)                       3 (5)                         0                        5 (8)     0
  Neutropenia, *n* (%)                  4 (6)                         1 (2)                    0         0
  Hypertension, *n* (%)                 6 (9)                         1 (2)                    10 (16)   4 (6)
  Diarrhea, *n* (%)                     15 (23)                       0                        17 (27)   0
  Hemorrhoids, *n* (%)                  1 (2)                         0                        4 (6)     0
  Stomatitis, *n* (%)                   16 (24)                       3 (5)                    7 (11)    1 (2)
  Nausea, *n* (%)                       3 (5)                         0                        3 (5)     1 (2)
  Hand--foot skin reaction, *n* (%)     27 (41)                       8 (12)                   32 (52)   6 (10)
  Alopecia, *n* (%)                     4 (6)                         0                        4 (6)     0
  Pruritus, *n* (%)                     3 (5)                         0                        4 (6)     0
  Piastrinopenia, *n* (%)               2 (3)                         0                        4 (6)     0
  Anorexia, *n* (%)                     3 (5)                         0                        1 (2)     0
  Hypophosphatemia, *n* (%)             4 (6)                         1 (2)                    3 (5)     0
  Blood amylase increase, *n* (%)       1 (2)                         0                        3 (5)     0
  Blood creatinine increased, *n* (%)   1 (2)                         0                        3 (5)     0
  Transaminase increase, *n* (%)        0                             0                        3 (5)     1 (2)
  Hyperuricemia, *n* (%)                4 (6)                         0                        6 (10)    0
  Arthralgia, *n* (%)                   5 (8)                         0                        0         0
  Dyspnoea, *n* (%)                     5 (8)                         0                        1 (2)     1 (2)

Abbreviation: IL-2=interleukin 2.
